Absolute Risk Reductions, Relative Risks, Relative Risk Reductions, and Numbers Needed to Treat Can Be Obtained From a Logistic Regression Model

J Clin Epidemiol. 2010 Jan;63(1):2-6. doi: 10.1016/j.jclinepi.2008.11.004. Epub 2009 Feb 20.

Abstract

Objective: Logistic regression models are frequently used in cohort studies to determine the association between treatment and dichotomous outcomes in the presence of confounding variables. In a logistic regression model, the association between exposure and outcome is measured using the odds ratio (OR). The OR can be difficult to interpret and only approximates the relative risk (RR) in certain restrictive settings. Several authors have suggested that for dichotomous outcomes, RRs, RR reductions, absolute risk reductions, and the number needed to treat (NNT) are more clinically meaningful measures of treatment effect.

Study design and setting: We describe a method for deriving clinically meaningful measures of treatment effect from a logistic regression model. This method involves determining the probability of the outcome if each subject in the cohort was treated and if each subject was untreated. These probabilities are then averaged across the study cohort to determine the average probability of the outcome in the population if all subjects were treated and if they were untreated.

Results: Risk differences, RRs, and NNTs were derived using a logistic regression model.

Conclusions: Clinically meaningful measures of effect can be derived from a logistic regression model in a cohort study. These methods can also be used in randomized controlled trials when logistic regression is used to adjust for possible imbalance in prognostically important baseline covariates.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Data Interpretation, Statistical
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Logistic Models*
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / mortality
  • Ontario / epidemiology
  • Risk Reduction Behavior*
  • Treatment Outcome

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors